AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 66 |
Market Cap | 1.23B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -9.17 |
PE Ratio (ttm) | -7.2 |
Forward PE | n/a |
Analyst | Buy |
Ask | 72 |
Volume | 252,025 |
Avg. Volume (20D) | 334,175 |
Open | 65.30 |
Previous Close | 64.02 |
Day's Range | 64.26 - 67.87 |
52-Week Range | 33.01 - 86.93 |
Beta | undefined |
About PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhib...
Analyst Forecast
According to 9 analyst ratings, the average rating for PRAX stock is "Buy." The 12-month stock price forecast is $150, which is an increase of 127.27% from the latest price.
Next Earnings Release
Analysts project revenue of $365.00K, reflecting a -29.13% YoY shrinking and earnings per share of -2.82, making a -5.05% decrease YoY.
2 months ago · seekingalpha.com
Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call TranscriptPraxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Dan Ferry - IR, LifeSci Communications Marcio Souza - President & CEO ...